Product
SumayaVac-1(SUM-101)
1 clinical trial
1 indication
Indication
MalariaClinical trial
A Randomised, Controlled, Double-blind, Parallel Group, Single Center Phase Ib Trial to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Dual-stage Malaria Vaccine, SumayaVac-1 (MSP-1 With GLA-SE as Adjuvant) in Healthy Malaria Exposed Adults of African Origin Aged 18-45 YearsStatus: Completed, Estimated PCD: 2024-04-02